Comprehensive live-cell imaging analysis of cryptotanshinone and synergistic drug-screening effects in various human and canine cancer cell lines.
Animals
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
Dogs
Early Detection of Cancer
/ methods
Humans
Neoplasms
/ drug therapy
Phenanthrenes
/ metabolism
STAT3 Transcription Factor
/ antagonists & inhibitors
Salvia miltiorrhiza
/ metabolism
Signal Transduction
/ drug effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
06
2020
accepted:
01
12
2020
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
9
7
2021
Statut:
epublish
Résumé
Several studies have highlighted both the extreme anticancer effects of Cryptotanshinone (CT), a Stat3 crippling component from Salvia miltiorrhiza, as well as other STAT3 inhibitors to fight cancer. Data presented in this experiment incorporates 2 years of in vitro studies applying a comprehensive live-cell drug-screening analysis of human and canine cancer cells exposed to CT at 20 μM concentration, as well as to other drug combinations. As previously observed in other studies, dogs are natural cancer models, given to their similarity in cancer genetics, epidemiology and disease progression compared to humans. Results obtained from several types of human and canine cancer cells exposed to CT and varied drug combinations, verified CT efficacy at combating cancer by achieving an extremely high percentage of apoptosis within 24 hours of drug exposure. CT anticancer efficacy in various human and canine cancer cell lines denotes its ability to interact across different biological processes and cancer regulatory cell networks, driving inhibition of cancer cell survival.
Sections du résumé
BACKGROUND
Several studies have highlighted both the extreme anticancer effects of Cryptotanshinone (CT), a Stat3 crippling component from Salvia miltiorrhiza, as well as other STAT3 inhibitors to fight cancer.
METHODS
Data presented in this experiment incorporates 2 years of in vitro studies applying a comprehensive live-cell drug-screening analysis of human and canine cancer cells exposed to CT at 20 μM concentration, as well as to other drug combinations. As previously observed in other studies, dogs are natural cancer models, given to their similarity in cancer genetics, epidemiology and disease progression compared to humans.
RESULTS
Results obtained from several types of human and canine cancer cells exposed to CT and varied drug combinations, verified CT efficacy at combating cancer by achieving an extremely high percentage of apoptosis within 24 hours of drug exposure.
CONCLUSIONS
CT anticancer efficacy in various human and canine cancer cell lines denotes its ability to interact across different biological processes and cancer regulatory cell networks, driving inhibition of cancer cell survival.
Identifiants
pubmed: 33544704
doi: 10.1371/journal.pone.0236074
pii: PONE-D-20-19784
pmc: PMC7864433
doi:
Substances chimiques
Phenanthrenes
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
cryptotanshinone
5E9SXT166N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0236074Déclaration de conflit d'intérêts
The authors have declared no competing interests exist.
Références
Vet Comp Oncol. 2009 Sep;7(3):162-72
pubmed: 19691645
J Comp Pathol. 2017 May;156(4):352-365
pubmed: 28449818
Expert Opin Drug Saf. 2013 Jul;12(4):589-603
pubmed: 23668378
J Microbiol. 2007 Aug;45(4):350-7
pubmed: 17846590
Vet Pathol. 2003 May;40(3):237-48
pubmed: 12724563
Vet Pathol. 2000 Jan;37(1):54-61
pubmed: 10643981
Cancer Prev Res (Phila). 2012 May;5(5):778-87
pubmed: 22490436
Apoptosis. 2011 Jul;16(7):696-707
pubmed: 21519916
Chem Biol Interact. 2017 Aug 1;273:48-55
pubmed: 28600121
Oncotarget. 2016 Nov 22;7(47):77998-78008
pubmed: 27793003
J Breast Cancer. 2015 Jun;18(2):112-8
pubmed: 26155286
Biomed Pharmacother. 2016 Aug;82:319-26
pubmed: 27470369
J Comp Pathol. 2016 Aug-Oct;155(2-3):156-170
pubmed: 27406312
BMC Cancer. 2009 Mar 10;9:81
pubmed: 19284568
Oncotarget. 2016 Feb 9;7(6):6521-37
pubmed: 26695547
Cancers (Basel). 2014 Jul 31;6(3):1579-96
pubmed: 25089666
J Gastroenterol Hepatol. 2000 May;15 Suppl:E67-70
pubmed: 10921385
Int J Cardiol. 2007 Sep 14;121(1):9-22
pubmed: 17363091
Pharmacol Ther. 2018 Aug;188:80-96
pubmed: 29378221
Mol Cancer Ther. 2008 Jan;7(1):90-100
pubmed: 18202012
J Biol Chem. 2013 Oct 11;288(41):29923-33
pubmed: 23986445
J Vet Intern Med. 2008 Jul-Aug;22(4):976-84
pubmed: 18564221
Int J Biol Macromol. 2013 Sep;60:268-71
pubmed: 23748011
Science. 1995 Jul 7;269(5220):81-3
pubmed: 7541555
Cancer Prev Res (Phila). 2010 Aug;3(8):1015-25
pubmed: 20628002
Phytomedicine. 2014 Sep 25;21(11):1264-72
pubmed: 25172788
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Res. 2016 Feb 1;76(3):652-63
pubmed: 26088127
Cancer Biol Ther. 2015;16(1):176-84
pubmed: 25482936
Asian Pac J Cancer Prev. 2014;15(6):2439-45
pubmed: 24761844
Apoptosis. 2014 Apr;19(4):615-28
pubmed: 24173372
Vet Comp Oncol. 2011 Sep;9(3):219-24
pubmed: 21848624
NCHS Data Brief. 2016 Aug;(254):1-8
pubmed: 27598767
Cell Death Dis. 2017 May 11;8(5):e2767
pubmed: 28492557
Xenobiotica. 2008 Apr;38(4):382-98
pubmed: 18340563
Anticancer Res. 2004 Sep-Oct;24(5A):3027-8
pubmed: 15517911
Oncotarget. 2018 Apr 24;9(31):22095-22112
pubmed: 29774125
Cancer Inform. 2016 Mar 09;14(Suppl 5):33-43
pubmed: 26997864
Vet J. 2013 Mar;195(3):366-72
pubmed: 22901454
J Agric Food Chem. 2017 Jul 26;65(29):5985-5993
pubmed: 28679204
BMC Genomics. 2009 Dec 23;10:625
pubmed: 20028558
ILAR J. 2018 Dec 1;59(1):99-110
pubmed: 30668709
Clin Cancer Res. 2002 Apr;8(4):945-54
pubmed: 11948098
J Vet Intern Med. 2018 Jan;32(1):361-369
pubmed: 29119628
Cancers (Basel). 2014 Apr 16;6(2):897-925
pubmed: 24743777
Cancer Res. 2009 Jan 1;69(1):193-202
pubmed: 19118003
Mol Cancer. 2015 May 01;14:100
pubmed: 25928246
ILAR J. 2014;55(1):69-85
pubmed: 24936031
J Ethnopharmacol. 2017 Mar 22;200:107-116
pubmed: 28088493
Oncotarget. 2017 Dec 14;9(3):3198-3213
pubmed: 29423040
BMC Genomics. 2009 Mar 27;10:135
pubmed: 19327144
Oncotarget. 2015 Nov 3;6(34):36400-17
pubmed: 26506415
Pigment Cell Melanoma Res. 2014 Jan;27(1):37-47
pubmed: 24128326
J Int Med Res. 2017 Feb;45(1):220-230
pubmed: 28222632
J Vet Diagn Invest. 2018 Sep;30(5):733-738
pubmed: 30027822
Mol Cell Biochem. 2015 Aug;406(1-2):63-73
pubmed: 25912550
Mol Med Rep. 2014 Jun;9(6):2447-52
pubmed: 24682389
Science. 2009 Jun 26;324(5935):1713-6
pubmed: 19556508
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47
pubmed: 27402769
Int J Cancer. 2011 Sep 1;129(5):1042-52
pubmed: 20848589
Oncotarget. 2017 Jul 25;8(30):50023-50033
pubmed: 28654902
Sci Rep. 2017 Jul 5;7(1):4709
pubmed: 28680091
Drug Des Devel Ther. 2017 Jun 15;11:1753-1766
pubmed: 28670110
J Biomed Opt. 2012 Apr;17(4):046008
pubmed: 22559686
J Ethnopharmacol. 2017 Jun 9;205:33-40
pubmed: 28456578
Biomed Pharmacother. 2018 Sep;105:1042-1049
pubmed: 30021339
Mol Med Rep. 2015 Nov;12(5):7782-8
pubmed: 26459366
Curr Drug Metab. 2007 May;8(4):365-78
pubmed: 17504224